


ALERCELL CELEBRATES NATIONAL CANCER SURVIVORS' DAY® 2023

A celebration of LIfe

BOZEMAN, MT, UNITED STATES, June 4, 2023 /EINPresswire.com/ -- Alercell celebrates today National Cancer Survivors' Day. National Cancer Survivors' Day Foundation invites all cancer survivors to celebrate this day and Alercell joins all survivors to celebrate another beautiful day of life. It is the 36th annual Celebrated.

Life with cancer is a rough road full of obstacles and challenges but also full of hope and expectations. "Today we are celebrating life" said Frederic Scheer Alercell CEO, a cancer patient himself.



Alercell wants to go further, Alercell believes that a world without cancer is within reach, but we need to modify our overall attitude toward cancer. Today we have made tremendous progress in curing and healing cancer, but we need to go further. We need to eliminate it completely like we



Today we are celebrating life"

Frederic Scheer

have done for numerous plagues before our time. It is possible and this is the mantra of Alercell: "Stop it before it starts!" It is possible.

Learn more about National Cancer Survivors' Day at: https://ncsd.org/

ABOUT ALERCELL


Alercell, Inc., a Montana company is a molecular diagnostics company pioneering novel therapeutics to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in Oncology in-vitro Diagnostic Testing and Neuroscience. The company was founded with the aim of providing more accurate and timely diagnostic tools for cancer patients

worldwide. Alercell's mission is to make a difference in the fight against cancer by providing innovative and accurate diagnostic solutions that improve patient outcomes.

The Alercell® mission is built on the foundation of "stopping it before it starts". Our genetics-based testing is the first line of assault against cancer & leukemia and infectious diseases. For more information, please visit: www.alercell.com and www. Lenadx.com

Forward-Looking Statements

This press release includes statements relating to Alercell RUO LENA Q51 [®] and its launch for Research Use Only. These statements and other statements regarding ALERCELL future plans and goals constitute "forward-looking statements" within the



meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals, other healthcare providers and pharmaceutical companies, the success of our commercialization efforts for the Research Use Only product offering, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Frederic Scheer Alercell Inc. +1 406-920-8787 email us here
Visit us on social media:
Facebook
LinkedIn
Instagram

This press release can be viewed online at: https://www.einpresswire.com/article/637633511

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.